This program aims to develop anti-CD11b therapeutic monoclonal antibody for immuno-oncology.
CD11b can mediate macrophage adhesion, migration, chemotaxis, and accumulation during the inflammatory processes. Scientists found CD11b contributes bone marrow cells development into a subtype of M1 macrophages, which a factor to prevent tumor growth. However, data have also shown that cancer cells interference with the CD11b activity and can convert bone marrow cells into M2 macrophages. Instead of suppressing tumor growth, M2 macrophages worthen the process. Because integrin CD11b and its role in macrophage polarization, it is believed, yet not proved, this integrin regulates the immune response during tumor progression.
Fig.1 CD11bs mediated the T cells response and programmed cell death process toward tumor environment.4
CD11b belongs to the β2-integrin subfamily, which presenting on myeloid cells. The β2-integrin subfamily is a leukocyte-specific receptor composed of different alpha subunits, CD11a, CD11b, CD11c, and CD11d, and a common beta subunit, CD18. CD11b has been identified as a negative regulator of immunosuppression and a target for cancer immunotherapy. Rationale highlighted below:
Here are some published data about CD11b working as a potential target for cancer immunotherapy.
Fig.2 BALB/c SCID mice inoculated with K7M2neo cells were untreated or administered Met on day 7 and injected with the indicated antibodies from days 19 to 34 at 5-day intervals.1
Fig.3 CD11b+Gr-1+ myeloid cells in lungs metastatic niche promote cancer cell colonization.2
Fig. 4. The anti-tumorigenic effect of CD11b antibody was assessed in a female athymic nude mouse xenograft model.3
We have extensive knowledge of end-to-end program development. For each program, we are committed to delivering the finalized program to our clients within 1.5 years before entering the IND stage.
Fig.5 Project pipeline management of therapeutic monoclonal antibody.
Creative Biolabs is looking for potential partners (include but not limit to major pharma or biotech firms) to develop anti-CD11b therapeutic monoclonal antibody program together. Our scientists are dedicated to bringing years of valuable experience to our partner and achieve a meaningful partnership. For any partners interest in our Next-IO™ programs, Creative Biolabs welcomes collaboration.
Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from the discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate for our programs.
With our quality control protocol and knowledge of global regulatory requirements, we can help our partners advance their programs with more chance to succeed. Look forward to cooperating with you in the near future.
For Research Use Only | Not For Clinical Use